Skip to content
2000
image of Single-cell and Bulk RNA-Seq Analyses Reveal TOMM7-mediated Multi-cell Death Mechanisms Driving Muscle-invasive Bladder Cancer Progression

Abstract

Introduction

Muscle-invasive bladder cancer (MIBC) is characterized by high malignancy and poor prognosis. Advances in single-cell RNA sequencing (scRNA-seq) have provided new insights into the molecular heterogeneity and progression of MIBC.

Methods

A single-cell atlas of bladder cancer (BCa) was constructed, and MIBC-related epithelial subclusters (Epi_MIBC) were identified. Key transcription factors and dysregulated cell death pathways were characterized. A prognostic model based on MIBC-related cell death genes (MIBC.CDGs) was developed using machine learning algorithms and validated across multiple cohorts. The functional role and druggability of TOMM7, a core gene, were evaluated through experiments and molecular docking analysis.

Results

The MIBC-related cell death score (MIBC.CDS) was shown to effectively stratify patient prognosis and predict immunotherapy response. Multiple cell death pathways were found to be activated in MIBC. Knockdown of TOMM7 suppressed proliferation, invasion, and migration in T24 cells, while modulating apoptosis, autophagy, mitophagy, cuproptosis, and ferroptosis. Molecular docking analysis identified sorafenib as a potential TOMM7-targeted therapeutic agent.

Discussion

The findings highlighted the critical role of cell death dysregulation in MIBC progression and underscored TOMM7 as a novel oncogenic regulator. The integration of multi-omics data and machine learning enhanced our understanding of tumor biology and provided a foundation for developing personalized treatment strategies.

Conclusion

TOMM7 was found to drive MIBC progression by regulating multiple cell death pathways. The MIBC.CDS may serve as a promising tool for prognostic evaluation and therapeutic stratification. Sorafenib was identified as a potential candidate for TOMM7-targeted therapy in MIBC.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/pra/10.2174/0115748928396718251104075645
2026-01-08
2026-02-26

  • From This Site

    /content/journals/pra/10.2174/0115748928396718251104075645
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sung H. Ferlay J. Siegel R.L. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660 33538338
    [Google Scholar]
  2. Dyrskjøt L. Hansel D.E. Efstathiou J.A. Bladder cancer. Nat. Rev. Dis. Primers 2023 9 1 58 10.1038/s41572‑023‑00468‑9 37884563
    [Google Scholar]
  3. Bladder cancer. Nat. Rev. Dis. Primers 2023 9 59 10.1038/s41572‑023‑00475‑w
    [Google Scholar]
  4. Lopez-Beltran A. Cookson M.S. Guercio B.J. Cheng L. Advances in diagnosis and treatment of bladder cancer. BMJ 2024 384 076743 10.1136/bmj‑2023‑076743 38346808
    [Google Scholar]
  5. Alfred Witjes J. Max Bruins H. Carrión A. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2023 guidelines. Eur. Urol. 2024 85 1 17 31 10.1016/j.eururo.2023.08.016 37858453
    [Google Scholar]
  6. Xing T. Li L. Chen Y. Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma. Cell Rep. Med. 2023 4 11 101264 10.1016/j.xcrm.2023.101264 37939712
    [Google Scholar]
  7. Guo J. Ma X. Liu D. A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis. Drug Resist. Updat. 2024 76 101116 10.1016/j.drup.2024.101116 38968684
    [Google Scholar]
  8. Lv J. Wu Q. Li K. Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune escape via STAT3/PD-L1 cascade. Int. J. Biol. Sci. 2023 19 12 3744 3761 10.7150/ijbs.87182 37564199
    [Google Scholar]
  9. Du W. Tu S. Zhang W. UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT. Int. J. Biol. Sci. 2024 20 4 1389 1409 10.7150/ijbs.83774 38385072
    [Google Scholar]
  10. Li F. Zhang H. Huang Y. Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer. Drug Resist. Updat. 2024 73 101059 10.1016/j.drup.2024.101059 38295753
    [Google Scholar]
  11. Yu H. Zhuang J. Zhou Z. METTL16 suppressed the proliferation and cisplatin-chemoresistance of bladder cancer by degrading PMEPA1 mRNA in a m6A manner through autophagy pathway. Int. J. Biol. Sci. 2024 20 4 1471 1491 10.7150/ijbs.86719 38385084
    [Google Scholar]
  12. Li D. Su H. Deng X. DARS2 promotes bladder cancer progression by enhancing PINK1-mediated mitophagy. Int. J. Biol. Sci. 2025 21 4 1530 1544 10.7150/ijbs.107632 39990673
    [Google Scholar]
  13. Zhang J. Huang Y. Tan X. Integrated analysis of multiple transcriptomic approaches and machine learning integration algorithms reveals high endothelial venules as a prognostic immune-related biomarker in bladder cancer. Int. Immunopharmacol. 2024 136 112184 10.1016/j.intimp.2024.112184 38824904
    [Google Scholar]
  14. Sun D. Guan X. Moran A.E. Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. Nat. Biotechnol. 2022 40 4 527 538 10.1038/s41587‑021‑01091‑3 34764492
    [Google Scholar]
  15. Zhao Y. Li Z.X. Zhu Y.J. Single‐cell transcriptome analysis uncovers intratumoral heterogeneity and underlying mechanisms for drug resistance in hepatobiliary tumor organoids. Adv. Sci. 2021 8 11 2003897 10.1002/advs.202003897 34105295
    [Google Scholar]
  16. Swanson K. Wu E. Zhang A. Alizadeh A.A. Zou J. From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatment. Cell 2023 186 8 1772 1791 10.1016/j.cell.2023.01.035 36905928
    [Google Scholar]
  17. Wang M. Chen X. Tan P. Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer. Cancer Cell 2022 40 9 1044 1059.e8 10.1016/j.ccell.2022.08.010 36099882
    [Google Scholar]
  18. Che G. Yin J. Wang W. Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics. Drug Resist. Updat. 2024 74 101080 10.1016/j.drup.2024.101080 38579635
    [Google Scholar]
  19. Deng X. Huang Y. Zhang J. Histone lactylation regulates PRKN-Mediated mitophagy to promote M2 Macrophage polarization in bladder cancer. Int. Immunopharmacol. 2025 148 114119 10.1016/j.intimp.2025.114119 39854875
    [Google Scholar]
  20. Song Q. Wang W. Yu H. IGF2BP3 promotes the proliferation and cisplatin resistance of bladder cancer by enhancing the mRNA stability of CDK6 in an m6A dependent manner. Int. J. Biol. Sci. 2025 21 5 2048 2066 10.7150/ijbs.103522 40083693
    [Google Scholar]
  21. Li J. Kong Z. Qi Y. Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8 + T-cell - Fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine learning: Bioinformatics multi-omics study. Int. J. Surg. 2024 110 8 4911 4931 10.1097/JS9.0000000000001516 38759695
    [Google Scholar]
  22. Koutros S. Kiemeney L.A. Choudhury P.P. Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights. Eur. Urol. 2023 84 1 127 137 10.1016/j.eururo.2023.04.020 37210288
    [Google Scholar]
  23. Tong X. Tang R. Xiao M. Targeting cell death pathways for cancer therapy: Recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J. Hematol. Oncol. 2022 15 1 174 10.1186/s13045‑022‑01392‑3 36482419
    [Google Scholar]
  24. Peng F. Liao M. Qin R. Regulated cell death (RCD) in cancer: Key pathways and targeted therapies. Signal Transduct. Target. Ther. 2022 7 1 286 10.1038/s41392‑022‑01110‑y 35963853
    [Google Scholar]
  25. Tang D. Kang R. Berghe T.V. Vandenabeele P. Kroemer G. The molecular machinery of regulated cell death. Cell Res. 2019 29 5 347 364 10.1038/s41422‑019‑0164‑5 30948788
    [Google Scholar]
  26. Taddei M.L. Giannoni E. Fiaschi T. Chiarugi P. Anoikis: An emerging hallmark in health and diseases. J. Pathol. 2012 226 2 380 393 10.1002/path.3000 21953325
    [Google Scholar]
  27. Lu Y. Li Z. Zhang S. Zhang T. Liu Y. Zhang L. Cellular mitophagy: Mechanism, roles in diseases and small molecule pharmacological regulation. Theranostics 2023 13 2 736 766 10.7150/thno.79876 36632220
    [Google Scholar]
  28. Stockwell B.R. Friedmann Angeli J.P. Bayir H. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 2017 171 2 273 285 10.1016/j.cell.2017.09.021 28985560
    [Google Scholar]
  29. Wang Y. Xie K. Chen W. Synergistic ferroptosis‐starvation therapy for bladder cancer based on hyaluronic acid modified metal–organic frameworks. Bioeng. Transl. Med. 2023 8 3 10515 10.1002/btm2.10515 37206228
    [Google Scholar]
  30. Tsvetkov P. Coy S. Petrova B. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science 2022 375 6586 1254 1261 10.1126/science.abf0529 35298263
    [Google Scholar]
  31. Liu X. Nie L. Zhang Y. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat. Cell Biol. 2023 25 3 404 414 10.1038/s41556‑023‑01091‑2 36747082
    [Google Scholar]
  32. Hänggi K. Ruffell B. Cell death, therapeutics, and the immune response in cancer. Trends Cancer 2023 9 5 381 396 10.1016/j.trecan.2023.02.001 36841748
    [Google Scholar]
  33. Wang Y. Chen Y. Zhang J. Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance. Drug Resist. Updat. 2024 72 101018 10.1016/j.drup.2023.101018 37979442
    [Google Scholar]
  34. Wang Y. Wu X. Ren Z. Overcoming cancer chemotherapy resistance by the induction of ferroptosis. Drug Resist. Updat. 2023 66 100916 10.1016/j.drup.2022.100916 36610291
    [Google Scholar]
  35. Wang Y. Cheng S. Fleishman J.S. Targeting anoikis resistance as a strategy for cancer therapy. Drug Resist. Updat. 2024 75 101099 10.1016/j.drup.2024.101099 38850692
    [Google Scholar]
  36. Niu X. You Q. Hou K. Autophagy in cancer development, immune evasion, and drug resistance. Drug Resist. Updat. 2025 78 101170 10.1016/j.drup.2024.101170 39603146
    [Google Scholar]
  37. Moyer A. Tanaka K. Cheng E.H. Apoptosis in Cancer Biology and Therapy. Annu. Rev. Pathol. 2025 20 1 303 328 10.1146/annurev‑pathmechdis‑051222‑115023 39854189
    [Google Scholar]
  38. Satija R. Farrell J.A. Gennert D. Schier A.F. Regev A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 2015 33 5 495 502 10.1038/nbt.3192 25867923
    [Google Scholar]
  39. Fu Y. Xue P. Ren M. Dong E. Harmony Loss for Unbalanced Prediction. IEEE J. Biomed. Health Inform. 2022 26 2 828 839 10.1109/JBHI.2021.3094578 34232895
    [Google Scholar]
  40. Huang Q. Liu Y. Du Y. Garmire L.X. Evaluation of Cell Type Annotation R Packages on Single-Cell RNA-Seq Data. Genomics Proteomics Bioinformatics 2021 19 2 267 281 10.1016/j.gpb.2020.07.004 33359678
    [Google Scholar]
  41. Jin S. Guerrero-Juarez C.F. Zhang L. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 2021 12 1 1088 10.1038/s41467‑021‑21246‑9 33597522
    [Google Scholar]
  42. Aibar S. Gonzalez-Blas C.B. Moerman T. SCENIC: Single-cell regulatory network inference and clustering. Nat. Methods 2017 14 11 1083 1086 10.1038/nmeth.4463 28991892
    [Google Scholar]
  43. Su K. Katebi A. Kohar V. NetAct: A computational platform to construct core transcription factor regulatory networks using gene activity. Genome Biol. 2022 23 1 270 10.1186/s13059‑022‑02835‑3 36575445
    [Google Scholar]
  44. Love M.I. Huber W. Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014 15 12 550 10.1186/s13059‑014‑0550‑8 25516281
    [Google Scholar]
  45. Mayakonda A. Lin D.C. Assenov Y. Plass C. Koeffler H.P. Maftools: Efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018 28 11 1747 1756 10.1101/gr.239244.118 30341162
    [Google Scholar]
  46. Langfelder P. Horvath S. WGCNA: An R package for weighted correlation network analysis. BMC Bioinformatics 2008 9 1 559 10.1186/1471‑2105‑9‑559 19114008
    [Google Scholar]
  47. Wilkerson M.D. Hayes D.N. ConsensusClusterPlus: A class discovery tool with confidence assessments and item tracking. Bioinformatics 2010 26 12 1572 1573 10.1093/bioinformatics/btq170 20427518
    [Google Scholar]
  48. Shen W. Song Z. Zhong X. Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. iMeta 2022 1 3 e36 10.1002/imt2.36 38868713
    [Google Scholar]
  49. Newman A.M. Liu C.L. Green M.R. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 2015 12 5 453 457 10.1038/nmeth.3337 25822800
    [Google Scholar]
  50. Geeleher P. Cox N. Huang R.S. pRRophetic: An R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One 2014 9 9 107468 10.1371/journal.pone.0107468 25229481
    [Google Scholar]
  51. Fustero-Torre C. Jiménez-Santos M.J. García-Martín S. Beyondcell: Targeting cancer therapeutic heterogeneity in single-cell RNA-seq data. Genome Med. 2021 13 1 187 10.1186/s13073‑021‑01001‑x 34911571
    [Google Scholar]
  52. Shimada K. Bachman J.A. Muhlich J.L. Mitchison T.J. shinyDepMap, a tool to identify targetable cancer genes and their functional connections from Cancer Dependency Map data. eLife 2021 10 57116 10.7554/eLife.57116 33554860
    [Google Scholar]
  53. He Y. Sun M.M. Zhang G.G. Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct. Target. Ther. 2021 6 1 425 10.1038/s41392‑021‑00828‑5 34916492
    [Google Scholar]
  54. Alzahrani A.S. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. Semin. Cancer Biol. 2019 59 125 132 10.1016/j.semcancer.2019.07.009 31323288
    [Google Scholar]
  55. Hu J. Cao J. Topatana W. Targeting mutant p53 for cancer therapy: Direct and indirect strategies. J. Hematol. Oncol. 2021 14 1 157 10.1186/s13045‑021‑01169‑0 34583722
    [Google Scholar]
  56. Stein Y. Rotter V. Aloni-Grinstein R. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis. Int. J. Mol. Sci. 2019 20 24 6197 10.3390/ijms20246197 31817996
    [Google Scholar]
  57. Chen Y. Song Y. Du W. Gong L. Chang H. Zou Z. Tumor-associated macrophages: An accomplice in solid tumor progression. J. Biomed. Sci. 2019 26 1 78 10.1186/s12929‑019‑0568‑z 31629410
    [Google Scholar]
  58. de Visser K.E. Joyce J.A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell 2023 41 3 374 403 10.1016/j.ccell.2023.02.016 36917948
    [Google Scholar]
  59. Rosenberg J.E. Hoffman-Censits J. Powles T. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 2016 387 10031 1909 1920 10.1016/S0140‑6736(16)00561‑4 26952546
    [Google Scholar]
  60. Chen D.S. Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature 2017 541 7637 321 330 10.1038/nature21349 28102259
    [Google Scholar]
  61. Rizvi N.A. Hellmann M.D. Snyder A. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 2015 348 6230 124 128 10.1126/science.aaa1348 25765070
    [Google Scholar]
  62. Valero C. Lee M. Hoen D. The association between tumor mutational burden and prognosis is dependent on treatment context. Nat. Genet. 2021 53 1 11 15 10.1038/s41588‑020‑00752‑4 33398197
    [Google Scholar]
  63. Baluapuri A. Wolf E. Eilers M. Target gene-independent functions of MYC oncoproteins. Nat. Rev. Mol. Cell Biol. 2020 21 5 255 267 10.1038/s41580‑020‑0215‑2 32071436
    [Google Scholar]
  64. Wang Y. Ju L. Wang G. DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC. Nat. Commun. 2023 14 1 2421 10.1038/s41467‑023‑38160‑x 37105989
    [Google Scholar]
  65. Dillen A. Bui I. Jung M. Agioti S. Zaravinos A. Bonavida B. Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1. Cancers (Basel) 2024 16 6 1237 10.3390/cancers16061237 38539569
    [Google Scholar]
  66. Goodarzi H. Liu X. Nguyen H.C.B. Zhang S. Fish L. Tavazoie S.F. Endogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via YBX1 Displacement. Cell 2015 161 4 790 802 10.1016/j.cell.2015.02.053 25957686
    [Google Scholar]
  67. Xu J. Ji L. Liang Y. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct. Target. Ther. 2020 5 1 298 10.1038/s41392‑020‑00375‑5 33361760
    [Google Scholar]
  68. Chen X. Li A. Sun B-F. 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs. Nat. Cell Biol. 2019 21 8 978 990 10.1038/s41556‑019‑0361‑y 31358969
    [Google Scholar]
  69. Hong X. Li Q. Li J. CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization. Clin. Cancer Res. 2022 28 20 4521 4535 10.1158/1078‑0432.CCR‑22‑0991 35917517
    [Google Scholar]
  70. Su H. Fan G. Huang J. Qiu X. LncRNA HOXC-AS3 promotes non-small-cell lung cancer growth and metastasis through upregulation of YBX1. Cell Death Dis. 2022 13 4 307 10.1038/s41419‑022‑04723‑x 35387975
    [Google Scholar]
  71. Yamashita T. Higashi M. Momose S. Morozumi M. Tamaru J.I. Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer. Int. J. Oncol. 2017 51 2 579 586 10.3892/ijo.2017.4031 28714514
    [Google Scholar]
  72. Krauß L. Urban B.C. Hastreiter S. HDAC2 Facilitates Pancreatic Cancer Metastasis. Cancer Res. 2022 82 4 695 707 10.1158/0008‑5472.CAN‑20‑3209 34903606
    [Google Scholar]
  73. Li L. Mei D.T. Zeng Y. HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin. Biomed. Pharmacother. 2016 84 284 290 10.1016/j.biopha.2016.09.030 27665474
    [Google Scholar]
  74. Jo H. Shim K. Kim H.U. Jung H.S. Jeoung D. HDAC2 as a target for developing anti-cancer drugs. Comput. Struct. Biotechnol. J. 2023 21 2048 2057 10.1016/j.csbj.2023.03.016 36968022
    [Google Scholar]
  75. Sekine S. Wang C. Sideris D.P. Bunker E. Zhang Z. Youle R.J. Reciprocal roles of Tom7 and OMA1 during mitochondrial import and activation of PINK1. Mol. Cell 2019 73 5 1028 1043.e5 10.1016/j.molcel.2019.01.002 30733118
    [Google Scholar]
  76. Li C.Y. Chen L.W. Tsai M.C. Homozygous variant in translocase of outer mitochondrial membrane 7 leads to metabolic reprogramming and microcephalic osteodysplastic dwarfism with moyamoya disease. EBioMedicine 2024 110 105476 10.1016/j.ebiom.2024.105476 39615461
    [Google Scholar]
  77. Yamano K. Matsuda N. Tanaka K. The ubiquitin signal and autophagy: An orchestrated dance leading to mitochondrial degradation. EMBO Rep. 2016 17 3 300 316 10.15252/embr.201541486 26882551
    [Google Scholar]
  78. Westermann B. Mitochondrial fusion and fission in cell life and death. Nat. Rev. Mol. Cell Biol. 2010 11 12 872 884 10.1038/nrm3013 21102612
    [Google Scholar]
  79. Su Q. Wang J. Wu Q. Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1α pathways in breast cancer. Phytomedicine 2021 84 153503 10.1016/j.phymed.2021.153503 33636580
    [Google Scholar]
  80. Ullah A. Aziz T. Ullah N. Nawaz T. Molecular Mechanisms of Sanguinarine in Cancer Prevention and Treatment. Anticancer. Agents Med. Chem. 2023 23 7 765 778 10.2174/1871520622666220831124321 36045531
    [Google Scholar]
  81. Ullah A. Shehzadi S. Ullah N. Hypoxia A Typical Target in Human Lung Cancer Therapy. Curr. Protein Pept. Sci. 2024 25 5 376 385 10.2174/0113892037252820231114045234 38031268
    [Google Scholar]
  82. Fan Y. Bergmann A. Apoptosis-induced compensatory proliferation. The Cell is dead. Long live the Cell! Trends Cell Biol. 2008 18 10 467 473 10.1016/j.tcb.2008.08.001 18774295
    [Google Scholar]
  83. Zhang C. Liu X. Jin S. Chen Y. Guo R. Ferroptosis in cancer therapy: A novel approach to reversing drug resistance. Mol. Cancer 2022 21 1 47 10.1186/s12943‑022‑01530‑y 35151318
    [Google Scholar]
  84. Wang S. Guo S. Guo J. Cell death pathways: Molecular mechanisms and therapeutic targets for cancer. MedComm 2024 5 9 e693 10.1002/mco2.693 39239068
    [Google Scholar]
/content/journals/pra/10.2174/0115748928396718251104075645
Loading
Single-cell and Bulk RNA-Seq Analyses Reveal TOMM7-mediated Multi-cell Death Mechanisms Driving Muscle-invasive Bladder Cancer Progression
Bentham Science Publishers ; https://doi.org/10.2174/0115748928396718251104075645
/content/journals/pra/10.2174/0115748928396718251104075645
/content/journals/pra/10.2174/0115748928396718251104075645
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: TOMM7 ; machine learning ; molecular docking ; Cell death ; single-cell RNA sequencing ; muscle-invasive bladder cancer

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test